Single-cell sequencing of brain tissues reveal the central nervous system’s susceptibility to SARS-CoV-2 and the drug

Zhichao Lu1,2†, Ziheng Wang1,2†, Zhuhuan Song3†, Chen Chen4, He Ma5, Peipei Gong2* and Yunzhao Xu1*

1Department of Clinical Biobank, Affiliated Hospital of Nantong University, Nantong, China, 2Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong, China, 3Department of Neurosurgery, Aviation General Hospital, Beijing, China, 4Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University and The Cancer Institute of Nanjing Medical University, Nanjing, China, 5Medical School of Soochow University, Suzhou, China

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the current COVID-19 pandemic, resulting in a public health crisis that required immediate action. The SARS-CoV-2 virus enters human cells via three receptors, namely cathepsin, angiotensin-converting enzyme 2 (ACE2) and SARS-CoV receptors. Cathepsin destroys the spike protein (S protein), thereby allowing the entry of viral nucleic acid into human host cells.

Methods: Utilizing single-cell transcriptome analysis of brain tissues, the vulnerability of the central nervous system to SARS-CoV-2 infection was investigated.

Results: ACE2 is mainly expressed in endothelial cells, with the highest levels found in ageing endothelial cells. Drug prediction suggests that (-)-catechin reduces the effects of COVID-19 on the nervous system. Immunohistochemistry analysis showed that ACE2 was mainly expressed in cerebral vessels. Immunofluorescence results showed the co-expression of CD31 and ACE2 in human tissues. Western blot further showed that ACE2 expression was higher in old rats than in young rats.

Conclusion: This study provides insight into the mechanism of SARS-CoV-2 brain invasion. Accordingly, patients with neurological symptoms who are infected with SARS-CoV-2 should be given individualised care.

KEYWORDS
SARS-CoV-2, single-cell, epigallocatechin, CNS, ACE2, catechins
Introduction

During the early days of December 2019, a novel transmittable infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly across China (Ladner et al., 2020). The World Health Organization (WHO) classified SARS-CoV-2 as a worldwide viral pandemic on 11 March 2020 (Lambertini et al., 2021; Omolayo et al., 2021). Millions of individuals globally have been impacted by the SARS-CoV-2 virus. SARS-CoV-2 infection is a heterogeneous illness (Bhattacharya and Thelma, 2020; Mavian et al., 2020), with extensive clinical characteristics, such as asymptomatic infection, septic shock, acute respiratory distress syndrome (ARDS), mild upper respiratory tract infection, multi-organ failure and mortality (Boras et al., 2021).

Respiratory viral infections, like other forms of viral infections, invade the central nervous system (CNS) via the hematoma or various neural retrograde routes. In terms of the CNS, it is infiltrated by a viral agent via the circulatory system. Moreover, certain viruses can invade neurons in the peripheral nervous system and then utilizes the axonal transport mechanism to obtain entry into the CNS (Schwerk et al., 2015; Dahm et al., 2016a). In the hematoma pathway, a virus can successfully invade the endothelium of the blood-brain barrier (BBB) or the epithelium of the blood-cerebrospinal fluid barrier (BCSFB) in the choroid plexus (CP), which is located in the ventricular system of the brain, or leukocytes, which can serve as a vector for dispersion towards the CNS (Argyris et al., 2007; Atluri et al., 2015). Furthermore, numerous SARS-COV-2-infected individuals experienced signs of neurological symptoms such as vomiting, nausea and headache. A clear association between these symptoms and unfavourable outcomes has been widely reported. Additionally, Moriguchi et al. presented the very first incidence of encephalitis/meningitis correlated with SARS-CoV-2 infection in the cerebrospinal fluid (CSF) that did not result in a reverse transcriptase (Liu et al., 2021). Based on the principle of reverse expression, catechin has the potential to prevent SARS-CoV-2 from entering the CNS.

Therefore, understanding the expression patterns of ACE2 in the nervous system is crucial in determining the neural system’s vulnerability to SARS-CoV-2 infection. This study examines the expression of ACE2 and associated genes in brain tissues, aiming to elucidate the susceptibility of the CNS to SARS-CoV-2 infection.

Materials and methods

Datasets

A single-cell RNA-seq expression profile of the mouse brain vascular system was obtained from the Gene Expression Omnibus (GEO) repository (GSE60361). The gene expression levels in each cell were analysed. Genes with an expression level of less than 0.1% of the total number of cells in the study were excluded. Eventually, 3005 cell samples from the dataset were selected for analysis, and the samples satisfied the quality control standards.

Clustering and dimensionality reduction

The Seurat package (version: 3.2.2) in the R software (version: 4.0.2) was utilized to conduct principal component analysis (PCA) using the PCEIbowPlot and JackStraw functions to identify key principal components (PCs). To determine gene heterogeneity in each cell group, the FindAllMarkers utility in Seurat was utilized. Following this, cell clustering and visual analysis of UMAP were performed utilizing the RunUMAP platform. The singleR package was subsequently utilized to annotate the marker genes, and CellMarker was thereafter employed to correct them based on their features.

Pathway and process enrichment analysis

Pathway and process enrichment analysis was performed using Metascape (https://metascape.org/gp/index.html). Pathways and processes enrichment studies were performed using the following ontology resources for the ACE2-related gene list: PANTHER Pathway, WikiPathways,
Transcription Factor Targets, PaGenBase, DisGeNET, TRRUST, CORUM, Canonical Pathways, Reactome Gene Sets, GO Biological Processes, KEGG Pathway and COVID. Moreover, all genes in the genome served as the enrichment background. To collect and classify terms based on their affiliation commonalities, a p-value less than 0.01, the least count of three and an enrichment factor of more than 1.5 (the enrichment factor denotes the ratio of the recorded counts and anticipated counts) were used. Furthermore, p-values were determined utilizing the accumulative hypergeometric distribution, whereas q-values were derived utilizing the Benjamini–Hochberg technique, which involves multiple tests. Kappa score was used for the hierarchical clustering of the enriched terms, wherein sub-trees with a similarity degree of more than 0.3 were deemed to be a cluster. The most significant statistical term inside a cluster was selected to serve as the cluster’s representative term (Hochberg and Benjamini, 1990).

Protein-protein interaction enrichment analysis

To obtain the gene list of ACE2-related proteins, PPI enrichment analysis was performed utilizing different databases, including InWeb_IM9, OmniPath8, BioGrid7, and

![Image](https://example.com/image.png)
Furthermore, only the physical interaction function was used in STRING (with a physical score greater than 0.132) and BioGrid databases. The resulting network comprised the selection of proteins that have established physical interplays with a minimum of one other component on the list. When the networks consisted of approximately 3–500 proteins, the Molecular Complex Detection (MCODE) method was employed to determine the components of the network that significantly correlated with each other (Bader and Hogue, 2003).

Small molecules identification

To predict relatively small active molecules that might attenuate the existing biological state of ACE2-related endothelial cells, an evaluation of the ACE2-related endothelial cells was performed via the comparison of the differentially expressed genes (DEGs) between clusters 4 and 13 against those found in the Connectivity Map database (CMap, http://www.broadinstitute.org/cmap/). Initially, the DEGs were classified into two groups, namely downmodulated and upmodulated groups. Subsequently, for gene set enrichment
analysis (GSEA), different expression significant probesets were selected from each group and evaluated, resulting in enrichment scores that ranged from $-1$ to $+1$. Furthermore, small molecules with positive connectivity values close to $+1$ were found to drive gene expression in cluster 13, while those with negative connectivity values close to $-1$ showed increased similarities between genes and small molecules, which might attenuate cluster 4’s status.

**Human protein atlas database analysis**

HPA (https://www.proteinatlas.org/) is a database containing details on cell and tissue distributions among the 24,000 proteins found in the human body. It employs specialised antibodies and immunohistochemical technologies to examine the dispersion and expression of every protein in 48 different types of normal human tissues, 12 different types of blood cells, 47 different types of cell lines and 20 different types of tumour tissues. These tissues are collected from 144 distinct normal and 216 distinct tumour tissues, thus guaranteeing that the immunohistochemical findings are representative of the population. Thus, using this database, both the prognostic value and protein expression levels of the most possible hub genes in brain tissues were validated.

**Immunofluorescence**

Juvenile Sprague–Dawley (SD) rats aged 4 weeks and old SD rats aged 12 months were selected and subsequently treated with intracardiac perfusion of 0.1 mmol phosphate-buffered saline (PBS) and 4% paraformaldehyde. Eight-micrometre coronal cryosections were incubated and blocked with 5% bovine serum albumin (BSA) for 2 h. Frozen sections were then incubated overnight at 4°C with primary antibodies. The primary antibodies used were anti-CD31 antibody (1:2000, Abcam, ab9498) and anti-ACE2 antibody (1:1000, Proteintech, 21115-1-AP). After overnight incubation, frozen sections were incubated with fluorescent secondary antibody (1:2000, Abcam) at room temperature for 2 h. Then, the sections were washed thrice with PBS and covered with fluorescent fixation medium containing 4′,6-diamidino-2-phenylindole (DAPI) (1:1000, Solarbio). Image acquisition was performed using an Olympus fluorescence microscope with an eyepiece magnification of $x10$ and an objective lens magnification of $x20$. The exposure time of each section was 20 ms. Particle fluorescence intensity of ACE2 was calculated using ImageJ software (National Institutes of Health, United States) after filming, and each group included six animals.
Western blot

Brain tissues from juvenile and aged SD rats were lysed in RIPA buffer (Solarbio, Beijing, China), following this protease and phosphatase inhibitors were added and then the sample was denatured at 100°C for 15 min. The protein samples were then separated using 10% sodium dodecyl-sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes. Next, PVDF membranes were blocked with 5% skim milk powder solution for 1 h, incubated with primary antibodies, including anti-ACE2 antibody (1:1000, Proteintech, 21115-1-AP) and anti-Tubulin antibody (1:10000, Abmart, M20005) overnight, followed by secondary antibodies (1:5000) for 2 h at room temperature. The bands were visualised using an ECL kit chemiluminescence reagent (Billerica Millipore, MA, United States). Protein band signals were detected using the Chemidoc detection system (Bio-Rad, Hercules, CA, United States) and quantified by the ImageJ software (National Institutes of Health, United States).

Results

Utilization of scRNA-seq data to analyze and identify 15 cell clusters in brain tissues

A total of 3,005 cells from 67 mice were acquired in this study. t-distributed stochastic neighbour embedding (t-SNE) technique was then used to divide the cells into 18 distinct clusters (Figure 1A). Differential expression analysis facilitated the identification of
marker genes of the 18 different cell clusters (|logFC| >1 and adjusted p-value < 0.05) (Figures 1B,C). Annotations of the types of cells in the 18 cell clusters were performed utilizing singleR and the CellMarker database (Figure 1D).

**Identification of two separate types of endothelial cells with unique biological functions and differentiation states**

Using ACE2 as the marker, individual brain cells were successfully identified. Cluster 4 (endothelial cells) showed the highest average expression of ACE2 (Figure 2A). The endothelial cells were classified into two groups, namely cluster 4 and cluster 13 (Figure 2B). Furthermore, a considerable differentiation propensity was observed between cluster 13 with low-ACE2-expression in the former branch and cluster 4 within the latter branch on performing pseudotime trajectory analysis. This suggests that ageing endothelial cells are more susceptible to the SARS-CoV-2 virus (Figures 2C,D).

DEGs of cluster 4 and cluster 13

To explore the expression model of cluster 4 and cluster 13, a Venn qplot was drawn to show the up-regulated genes and downregulated genes in each cluster (Figure 2G). Genes with opposite expressions were considered to be DEGs in these two classifications.

**Enrichment analyses**

For a thorough understanding of the biological mechanisms of DEGs between clusters 4 and 13, Metascape was used to conduct GO and KEGG pathway enrichment analyses. The DEGs were found to be mostly enriched in the ensheathment of neurons, oligodendrocyte differentiation and oligodendrocyte specification, leading to myelin components for CNS, small molecule biosynthetic process, and organic hydroxy compound biosynthetic process (Figures 3A,B).

**Establishment of the PPI network, module analysis and localization**

The PPI network for the DEGs and MCODE showed that TUBB4A, TSPAN2, TALDO1, SC5D, PSAT1, PHGDH, MSMO1, MBP, MAG, KCNA1, ERMN and CD9 play a key role in SARS-CoV-2 infection (Figure 3C). Moreover, the hub genes are highly expressed in some astrocytes. The interaction of endothelial cells and...
astrocytes can cause SARS-COV-2 to enter the CNS. The expression of these hub genes among cell subsets is shown in Figures 4A,B.

Identification of related active small molecules

The DEG data that had been classified into the upregulated and downregulated groups were entered into the CMap database, where it was subjected to further integration with small molecule treatments to evaluate and identify potential therapeutic medicines for ACE2-related endothelial cells. Figure 5A illustrate the top 20 relevant small molecules and their enrichment scores, respectively. A significant negative score was found to be associated with the small molecules of phenanthridinone (enrichment score = −0.954) and (−)-catechin (enrichment score = −0.977), suggesting that these molecules characterize cluster 13. These prospective small molecule medications have the capacity of attenuating gene expression, thereby identifying potential novel pathways and molecular processes for innovative targeted treatments focusing on the CNS. However, further research is required to determine the specific significance of these potential small compounds.

ACE2 protein expression in the brain

Furthermore, utilizing clinical samples from the HPA repository, the ACE2 protein expression level was determined. Immunohistochemical results showed that the gene was mainly expressed in cerebral vessels (Figure 5B). Representative images of immunofluorescence staining for CD31 (red), ACE2 (green) and DAPI (blue) in the young and aged Sprague–Dawley (SD) rats are shown in Figure 6A. Additionally, immunofluorescence showed that ACE2 was mainly expressed in endothelial cells and was significantly highly expressed in the brain endothelium of aged rats compared to that of young rats (p < 0.0001; Figures 6B,C). Furthermore, the western blot results showed that ACE2 expression in the brain in aged rats was significantly higher than that in young rats (Figures 6C,D).

Discussion

Respiratory viruses are capable of infecting the upper respiratory system in humans, resulting in mild illnesses in most cases (Gunathilake et al., 2021). However, in susceptible groups, such as neonates, infants, older adults and immunocompromised individuals, these pathogens may also impact the lower respiratory tract, resulting in more serious
infections such as pneumonia (Desforges et al., 2019). Furthermore, due to the virus's ability to adapt quickly and transcend the species barrier, most of these infections, including SARS-CoV and influenza A, have sometimes caused epidemics or pandemics. They have also been correlated with more significant clinical illnesses and even death (Berth et al., 2009). Additionally, various studies over decades have reported that certain respiratory viruses have neural-invasive abilities, indicating that they may migrate from the respiratory system into the CNS (Dahm et al., 2016b). Viruses that infect human CNS cells can subsequently induce various forms of encephalopathy, such as encephalitis and long-term neurologic illnesses. Although various therapeutic compounds are currently being investigated, there remains a scarcity of effective and reliable therapeutic regimens to treat SARS-CoV-2. Moreover, studies regarding SARS-CoV-2 in the CNS remain scarce.

Generally, an infection stimulates the endothelial cells to release chemokines, which improves vascular permeability and allows viruses to get through the first layer of the BBB (Mladinich et al., 2021). Furthermore, viruses commonly employ proteins produced by the endothelium and enter these cells. While SARS-CoV-2 infections are commonly limited to the airways, it has been reported to cross the epithelial barrier and infiltrate the CNS. This is consistent with the mechanism of other respiratory viral pathogens, such as influenza virus, Nipah virus and respiratory syncytial virus (RSV). In this study, brain endothelial cells showed significant expression levels of the enzyme ACE2. The SARS-CoV-2 virus enters the host cell via the SARS-CoV receptor ACE2. Hence, it was speculated that SARS-CoV-2 employs the ACE2 receptor for intracellular penetration into the CNS by infecting endothelial cells. The time analysis of cells showed that endothelial cells in the advanced stage had higher expressions of ACE2. This suggests that elderly patients are more likely to be infected by SARS-CoV-2 via the endothelial cells of the CNS.

Several patients with SARS-CoV-2 (i.e., who had a positive RT-PCR test) also experienced the loss of smell, despite not experiencing nasal obstruction dysgeusia, albeit exhibiting swelling in the olfactory cleft, which was validated using magnetic resonance imaging. The olfactory cleft is responsible for the flow of odours to the olfactory epithelium and then to the olfactory bulb. The olfactory epithelium (commonly referred to as the olfactory mucosa) consists of olfactory receptor neurons, basal cells and epithelial cells, all of which function together to create ‘smell’. When TNF-alpha (TNF-α) and interleukin-1 beta (IL1β) are released, the above cells react to create a “smell”. Notably, SARS-CoV-2 infection has been demonstrated to contribute to a higher production of TNF-α and IL1β. Consequently, the pathogenesis of SARS-CoV-2 could impact the lower respiratory tract while simultaneously impacting surrounding cells (such as those found in the respiratory tract), resulting in affecting the CNS.

Increasing evidence has identified the SARS-CoV-2 virus as the source of EGCG’s antiviral effects (Upadhyay et al., 2020). Furthermore, it has been shown that EGCG attenuated the enzymatic activities of the coronavirus 3CL protease, preventing the virus from replicating. Moreover, EGCG has the ability to control particular targets such as the RdRp and viral S protein. It has also been shown to be effective in preventing the reproduction of SARS-CoV-2 in cell incubation experiments. Molecular docking studies also show that EGCG inhibits SARS-CoV-2 entry into the target cell by interfering with the RBD in the viral membrane that binds to ACE2. This study suggests that EGCG could prevent SARS-CoV-2 from entering the CNS through endothelial cells by inhibiting its expression. In order to verify the utility of EGCG in anti-SARS-CoV-2 treatments, more pre-clinical investigations, clinical trials and epidemiological analyses are necessary.

The findings in the present research are restricted as only mouse tissue samples were used. Nonetheless, this study provides proof that SARS-CoV-2 could infiltrate the CNS through a large number of susceptible cells. Moreover, endothelial cells in elderly patients have a greater susceptibility to infection by SARS-CoV-2. Furthermore, the influence of SARS-COV-2 on the CNS requires more attention.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Ethics statement

The animal study was reviewed and approved by The animal study was reviewed and approved by the Nantong University Animal Ethics Committee. (S20180220-002).

Author contributions

The lead authors, including ZW and ZL, took charge of the analysis and drafting of the manuscript. ZS performed the preliminary statistical analysis, drafted the first and final drafts, and responded to the reviewer comments. HM and CC were in charge of data collecting and organizing, and they all had a role in writing the final revisions of the text. YX and PG were responsible for organizing the funding, designing the initial concept, and contributing to the writing of final drafts.
Funding

This work was supported by China Postdoctoral Science Foundation (2020M670040ZX), Science and Technology Innovation and Demonstration Promotion Project of Natural Science of Nantong City (MS22021004) and Project of Jiangsu Provincial Health Commission (HS2019058).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Argrysis, E. G., Acheampong, E., Wang, F., Huang, J., Chen, K., Mukhtar, M., et al. (2007). The interferon-induced expression of APOBEC3G in human brain-borne virus exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virolgy 367 (2), 440–451. doi:10.1016/j.virol.2007.06.810

Athuri, V. S., Hidalgo, M., Samikkanu, T., Kurapati, K. R. V., Jayant, R. D., Sagar, V., et al. (2015). Effect of human immunodeficiency virus on blood-brain barrier integrity and function: an update. Front. Cell. Neurosci. 9, 212. doi:10.3389/fncel.2015.00212

Bader, G. D., and Hogue, C. W. (2003). An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 4, 2. doi:10.1186/1471-2105-4-2

Berth, S. H., Leopold, P. L., and Morfini, G. N. (2009). Virus-induced neuronal dysfunction and degeneration. Front. Biosci. 14, 5239–5259. doi:10.2741/3595

Bhattacharyya, U., and Thelma, B. K. (2020). Age-related gene expression alterations by SARS-CoV-2 infection contribute to poor prognosis in elderly. J. Genet. 99 (1), 80. doi:10.1016/j/jogent.2020.01.013

Boras, B., Jones, R. M., Anson, B. J., Arenson, D., Aschenbrenner, L., Bakowski, M. A., et al. (2021). Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID-19. Nat. Commun. 12 (1), 6055. doi:10.1038/s41467-021-26239-2

Dahm, T., Rudolph, H., Schwer, C., Schrotten, H., and Tenenbaum, T. (2016). Neuroinflammation and invasion in viral central nervous system infections. Mediat. Inflamm. 2016, 8562805. doi:10.1155/2016/8562805

Dahm, T., Rudolph, H., Schwer, C., Schrotten, H., and Tenenbaum, T. (2016). Neuroinflammation and invasion in viral central nervous system infections. Mediat. Inflamm. 2016, 8562805. doi:10.1155/2016/8562805

Desforges, M., Le Coupagnac, A., Dubois, P., Bourgouin, A., Lajoie, L., Dube, M., et al. (2019). Human coronaviruses and other respiratory viruses: Underestimated opportunistic pathogens of the central nervous system? Viruses 12 (1), E14. doi:10.3390/v12010014

Gunathilake, T., Ching, Y. C., Uyama, H., and Chua, C. H. (2021). Nanotherapeutics for treating coronavirus diseases. J. Drug Deliv. Sci. Technol. 64, 102634. doi:10.1016/j.jddst.2021.102634

Hochberg, Y., and Benjamini, Y. (1990). More powerful procedures for multiple significance testing. Stat. Med. 9 (7), 811–818. doi:10.1002/sim.4780090710

Ladner, J. T., Larsen, B. B., Bowers, J. R., Hepp, C. M., Bolyen, E., Folkerts, M., et al. (2020). An early pandemic analysis of SARS-CoV-2 population structure and dynamics in Arizona. mBio 11 (5), e02107-20. doi:10.1128/mBio.02107-20

Lambertini, M., Patrizi, A., Perin, K., Marasco, G., Toselli, M., Marcelli, E., et al. (2021). The impact of the COVID-19 pandemic on dermatologic practice: an Italian survey. Eur. J. Dermatol. 31 (1), 55–59. doi:10.1684/ejd.2021.3970

Li, T., Wernersson, R., Hansen, R. B., Horn, H., Mercer, J., Slodkowicz, G., et al. (2017). A scored human protein-protein interaction network to catalyze genomic interpretation. Nat. Methods 14 (1), 61–64. doi:10.1038/nmeth.4083

Liu, S. Y., Wang, W., Ke, J. P., Zhang, P., Chu, G. X., and Bao, G. H. (2021). Discovery of Camellia sinensis catechins as SARS-CoV-2 3CL protease inhibitors through molecular docking, intra and extra cellular assays. Phytomedicine. 96, 153853. doi:10.1016/j.phymed.2021.153853

Mavian, C., Marini, S., Prosperi, M., and Salemi, M. (2020). A snapshot of SARS-CoV-2 genome availability up to April 2020 and its implications: Data analysis. JMIR public health surveillance 6 (2), e219170. doi:10.2196/19170

Miladinich, M. C., Conde, J. N., Schutt, W. R., Sohn, S. Y., and Mackow, E. R. (2021). Blockade of autocrine CCL5 responses inhibits Zika virus persistence and spread in human brain microvascular endothelial cells. mBio 12 (4), e0196221. doi:10.1128/mbio.01962-21

Moriguchi, T., Harui, N., and Goto, J. (2020). A first case of meningitis/encephalitis associated with SARS-CoV-2. Int. J. Infect. Dis. IJDH 94, 55–58. doi:10.1016/j.ijid.2020.03.062

Omoloaye, T. S., Adeniji, A. A., Cardona Maya, W. D., and du Plessis, S. S. (2021). SARS-COV-2 (Covid-19) and male fertility: Where are we? Reprod. Toxicol. 99, 65–70. doi:10.1016/j.reprotox.2020.11.012

Oughtred, R., Stark, C., Breitkreuz, B. J., Rust, J., Boucher, L., Chang, C., et al. (2019). The BioGRID interaction database: 2019 update. Nucleic Acids Res. 47 (D1), D529-D541. doi:10.1093/nar/gky1079

Schwer, C., Tenenbaum, T., Kim, K. S., and Schrotten, H. (2015). The choroid plexus-a multi-role player during infectious diseases of the CNS. Front. Cell. Neurosci. 80, 80. doi:10.3389/fncel.2015.00080

Szkarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., et al. (2019). STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47 (D1), D607–D613. doi:10.1093/nar/gky1131

Upadhyay, S., Tripathi, P. K., Singh, M., Raghavendrahar, S., Bhardwaj, M., and Patel, A. K. (2020). Evaluation of medicinal herbs as a potential therapeutic option against SARS-CoV-2 targeting its main protease. Phytother. Res. 34 (12), 3411–3419. doi:10.1002/ptr.6802

Wang, Y. Q., Li, Q. S., Zheng, X. Q., Lu, J. L., and Liang, Y. R. (2021). Antiviral effects of green tea EGCG and its potential application against COVID-19. Mol. Biol. Cell. Switz. 26 (13), 3962. doi:10.3390/62133962

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.971017/full#supplementary-material